Novartis Unit Sandoz Receives Positive CHMP Opinion For Multiple Sclerosis Biosimilar Natalizumab
Portfolio Pulse from Charles Gross
Sandoz, a unit of Novartis, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for marketing authorization for its biosimilar natalizumab. The authorization covers treatment for adults with highly active relapsing-remitting multiple sclerosis.
July 24, 2023 | 8:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis' unit Sandoz has received a positive opinion for its biosimilar natalizumab, which could potentially boost Novartis' revenues.
The positive opinion from CHMP for Sandoz's biosimilar natalizumab indicates a likely approval for marketing in the European Union. This could potentially increase Novartis' revenues as it opens up a new market for the company.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
The positive opinion for Sandoz's biosimilar natalizumab could potentially impact the European market, which could indirectly affect the Vanguard FTSE Europe ETF (VGK).
While the news directly impacts Novartis, it could indirectly affect VGK as it pertains to the European market. However, the impact is likely to be minimal as VGK is a diversified ETF and the news is specific to one company and one product.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50